Phase I/II Combination With Irinotecan- Erbitux

NCT00594984 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer (MCRC)

Interventions

DRUG: Cetuximab
DRUG: Irinotecan
DRUG: Brivanib
DRUG: Brivanib
DRUG: Brivanib Placebo

Sponsor

Bristol-Myers Squibb